Skip to main content
ANIP logo

ANI Pharmaceuticals, Inc. (ANIP) Stock: Price, Forecast & Analyst Target

ANI Pharmaceuticals, Inc. (ANIP) — MoonshotScore 94/100 (Exceptional band), calculated Nov 18, 2026. Price $68.55 (-0.84%), as of the Nov 20, 2026 trading session; market cap $1.56B.

Educational signal · not a buy or sell recommendation · How to read this

$68.55 −$0.58 (-0.84%) Market Cap $1.56B

ANI Pharmaceuticals, Inc. · ANIP · NASDAQ

ANI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and manufacturing branded and generic prescription pharmaceuticals, particularly in controlled substances and oncology. The company operates primarily in the U.S. and Canada, leveraging a diverse product portfolio and contract manufacturing capabilities.

Price as of Nov 20, 2026

Key Statistics

94 of 100

MoonshotScore v2 · ANI Pharmaceuticals (ANIP)

Exceptional
Business Quality Elite (90)
Financial Safety Sound (74)
Valuation Cheap (86)
Growth Durability Compounding (98)
Momentum Rising (67)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a strong balance sheet and elite growth, at a cheap price, with no real weak spot. Business Quality: Elite; Financial Safety: Sound; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.

  • quarterly revenue $228M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 2.58 · Piotroski F 8

Helping: business quality, balance-sheet strength, an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ANIP (58 recorded, newest six shown)
RecordedScoreBand
96Exceptional
96Exceptional
96Exceptional
94Exceptional
94Exceptional
94Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$68.55
Change on the day-0.84%
Market capitalisation$1.56B—
Price / earnings (trailing)13.51
Shares traded on the day227.3K

Price & events

Other perspectives

Council score for ANI Pharmaceuticals (ANIP): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Strong
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Neutral
Debt/Equity Weak
ROE Moderate
Gross Margin Strong

Read on: Nov 21, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is ANI Pharmaceuticals (ANIP), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ANI Pharmaceuticals, Inc. (ANIP) is listed on NASDAQ. It employs 970 people. In Q3 FY2025 it reported revenue of $228M and net income of $27M. The market values it at $1.56B.

2 · Latest results

What do the latest results show for ANI Pharmaceuticals (ANIP)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $228M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$228M$27M$1.25 (diluted)
Q4 FY2025$247M$27M$0.96 (diluted)
Q1 FY2026$237M$29M$1.37 (diluted)
Q2 FY2026$266M$25M$1.05 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for ANI Pharmaceuticals (ANIP)?

Short answer

The MoonshotScore pillars rate business quality, balance-sheet strength, an attractive price, durable growth as strengths. The distress and quality screens read Altman Z 2.58 · Piotroski F 8. Trailing ratios: ROE 20.4% · ROA 6.4% · current ratio 2.75.

4 · What to check next?

What should you watch next at ANI Pharmaceuticals (ANIP)?

Short answer · as of

Current published price targets run low $85.00 · high $119.00 · consensus $99.50 · median $97.00 against a quoted price of $68.55 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Nov 7, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does ANI Pharmaceuticals compare with its peers?

Short answer

ANI Pharmaceuticals's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Cronos Group Inc. (CRON) Same industry, near in market value$3.08 Nov 19, 2026$1.13B95 5-pillar Nov 18, 2026
ANI Pharmaceuticals (ANIP) — this page$68.55$1.56B94
McKesson Corporation (MCK) Named competitor$1069.43 Nov 20, 2026$123B92 5-pillar Nov 18, 2026
Pacira BioSciences, Inc. (PCRX) Same industry, near in market value$36.48 Nov 20, 2026$1.46B92 5-pillar Nov 18, 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Same industry, near in market value$28.11 Nov 19, 2026$1.20B86 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.80 Nov 20, 2026$120B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$438.82 Nov 19, 2026$237B84 5-pillar Nov 18, 2026
CVS Health Corporation (CVS) Named competitor$80.84 Nov 20, 2026$103B81 5-pillar Nov 18, 2026
Phibro Animal Health Corporation (PAHC) Same industry, near in market value$33.29 Nov 20, 2026$1.35B78 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$166.53 Nov 19, 2026$207B72 5-pillar Nov 18, 2026
HUTCHMED (China) Limited (HCM) Same industry, near in market value$13.22 Nov 20, 2026$2.30B70 5-pillar Nov 18, 2026
Collegium Pharmaceutical, Inc. (COLL) Same industry, near in market value$25.21 Nov 19, 2026$783M58 5-pillar Nov 18, 2026
Regencell Bioscience Holdings Limited (RGC) Same industry, near in market value$4.36 Nov 19, 2026$2.16B47 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$85.00 – $119.00
Consensus target
$99.50
Median target
$97.00

Consensus record · Captured .

Measured against a quoted price of $68.55 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 29, 2026

Transactions
24
Identified insiders
7
Purchases
0
Sales
18
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ANIP in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ANIP in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about ANI Pharmaceuticals (ANIP)?

Read these with our analysis →

Common Questions About ANIP

These answers are editorial: 1 of these 9 answers is drawn from the ANIP research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ANIP?

ANIP carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is ANIP a good stock to buy?

Stock Expert AI does not rate ANIP buy, sell or hold. ANI Pharmaceuticals, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ANIP stock price today?

The last price recorded for ANI Pharmaceuticals, Inc. (ANIP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ANIP price target?

The analyst consensus price target for ANI Pharmaceuticals, Inc. (ANIP), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

How does ANI Pharmaceuticals, Inc. navigate regulatory approval processes?

ANI Pharmaceuticals, Inc. maintains a strong compliance strategy to navigate the complex regulatory landscape of the pharmaceutical industry. The company has a track record of successful FDA approvals and adheres to stringent quality standards, ensuring that its products meet all necessary regulatory requirements for safety and efficacy.

What are the key factors to evaluate for ANIP?

ANI Pharmaceuticals, Inc. (ANIP) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Expansion in Oncology: ANI Pharmaceuticals is poised to expand its oncology product line, which is projected to grow significantly as cancer prevalence increases. Not financial advice.

How frequently does ANIP data refresh on this page?

ANIP's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ANIP's recent stock price performance?

ANI Pharmaceuticals, Inc. (ANIP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across various therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ANIP overvalued or undervalued right now?

The trailing P/E of ANI Pharmaceuticals, Inc. (ANIP) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.